https://m2.mtmt.hu/ eng 2026-05-26 02:42 JournalArticle 32946435 VALIDATED true Funding Agency and Grant Number: Central Eastern European Academy of Oncology Foundation; National Institute of Oncology Funding text: The publication fee is covered by funding of the Central Eastern European Academy of Oncology Foundation, National Institute of Oncology 1122 Budapest Rath Gy. u 7-9. 0 false 2026-05-22T00:36:04.644+0000 2025-11-03T12:46:11.105+0000 2022-07-14T08:33:29.675+0000 true 10070075 Nádas Orsolya /api/admin/10070075 Admin Orsolya Nádas (OOI admin4) true 2025-11-04T08:56:22.215+0000 2025-11-04T08:56:22.215+0000 2024-02-22T13:40:02.487+0000 true 10015546 Berhidi Anna /api/admin/10015546 Admin Anna Berhidi (SE_KK_Admin5_BA, admin) true 10015546 Admin 10067876 /api/admin/10067876 Gusztáv Ladányi (MTMT API user, admin) Ladányi Gusztáv true true Admin 10080105 /api/admin/10080105 Katalin Kériné Tornyi (MTMT ellenőrzés admin5) Kériné Tornyi Katalin true true 2024-10-17T16:16:12.275+0000 true false true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle true 10000359 Study Group true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle /api/subtype/10000359 Sokszerzős vagy csoportos szerzőségű szakcikk SubType Study Group (Journal Article) 104 true 10000359 true 1 /api/category/1 Category Scientific true 1 Rubovszky, Gábor true true /api/journal/1035680 REVIEWED PATHOLOGY AND ONCOLOGY RESEARCH 1219-4956 1532-2807 true false 1035680 false 1035680 true 1219-4956 1532-2807 Journal FOREIGN_AND_HUNGARIAN 28 1610383 1610383 26 2022 true 2022 true true true false true false GOLD 2026-05-22 true https://doi.org/10.3389/pore.2022.1610383 24 0 24 17 8 24 23 23 20 24 24 17 17 17 7 0 24 17 24 17 0 10 10 Folyóiratcikk Journal Article 24 24 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2022 0 6 1 6 1 2023 0 9 7 9 7 2024 0 4 4 4 4 2025 0 2 2 2 2 2026 0 3 3 3 3 Q2 false false false false 2022-07-28T12:14:28.380+0000 Belgyógyászati és Onkológiai Klinika (SE / AOK / K); Fizioterápiai Tanszék (SE / ETK2007); Magatartástudományi Intézet (SE / AOK / I); Onkológiai Tanszék (SE / AOK / K); Onkoterápiás Intézet (PTE / ÁOK); Onkoterápiás Klinika (SZTE / SZAOK); Országos Onkológiai Intézet; Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I); Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I) 12 53 9 14 6 true 10080105 10067876 Language 10002 /api/language/10002 English Angol English true 2 true PersonAuthorship 102439557 /api/authorship/102439557 Rubovszky, Gábor ✉ [Rubovszky, Gábor (klinikai onkológia), author] National Institute of Oncology 1 0.071 true false true Author 10060070 /api/author/10060070 Gábor Rubovszky (klinikai onkológia) Rubovszky Gábor true 10060070 true Rubovszky Gábor true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439558 /api/authorship/102439558 Kocsis, Judit* 2 0.071 true false false Kocsis Judit true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439559 /api/authorship/102439559 Boér, Katalin [Boér, Katalin (Klinikai Orvostud...), author] 3 0.071428575 false false false Author 10048974 /api/author/10048974 Katalin Boér (Klinikai Orvostudomány) Boér Katalin true 10048974 true Boér Katalin true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439560 /api/authorship/102439560 Chilingirova, Nataliya 4 0.071428575 false false false Chilingirova Nataliya true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439561 /api/authorship/102439561 Dank, Magdolna [Dank, Magdolna (onkológia), author] Department of Internal Medicine and Oncology (SU / FM / C) 5 0.071 false false false Author 10011481 /api/author/10011481 Magdolna Dank (onkológia) Dank Magdolna true 10011481 true Dank Magdolna true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439562 /api/authorship/102439562 Kahán, Zsuzsanna [Kahán, Zsuzsanna (Elméleti orvostud...), author] Department of Oncotherapy (SZTE / ASZMS) 6 0.071428575 false false false Author 10013805 /api/author/10013805 Zsuzsanna Kahán (Elméleti orvostudomány) Kahán Zsuzsanna true 10013805 true Kahán Zsuzsanna true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439563 /api/authorship/102439563 Kaidarova, Dilyara 7 0.071428575 false false false Kaidarova Dilyara true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439564 /api/authorship/102439564 Kövér, Erika [Kövér, Erika (Onkológia), author] Department of Oncotherapy (UP / UPMS) 8 0.071 false false false Author 10025719 /api/author/10025719 Erika Kövér (Onkológia) Kövér Erika true 10025719 true Kövér Erika true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439565 /api/authorship/102439565 Krakovská, Bibiana Vertáková 9 0.071428575 false false false Krakovská Bibiana Vertáková true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439566 /api/authorship/102439566 Máhr, Károly [Máhr, Károly (Onkológia), author] 10 0.071428575 false false false Author 10035708 /api/author/10035708 Károly Máhr (Onkológia) Máhr Károly true 10035708 true Máhr Károly true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439567 /api/authorship/102439567 Mriňáková, Bela 11 0.071428575 false false false Mriňáková Bela true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439568 /api/authorship/102439568 Pikó, Béla 12 0.071428575 false false false Pikó Béla true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439569 /api/authorship/102439569 Božović-Spasojević, Ivana 13 0.071428575 false false false Božović-Spasojević Ivana true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 102439570 /api/authorship/102439570 Horváth, Zsolt [Horváth, Zsolt (Onkológia), author] 14 0.071 false true false Author 10026959 /api/author/10026959 Zsolt Horváth (Onkológia) Horváth Zsolt true 10026959 true Horváth Zsolt true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true OrgAuthorship 103018264 /api/authorship/103018264 Central-Eastern European Academy of Oncology (CEEAO) International Professional Panel [Collaborative Organization] 15 0.0 false false true false false AuthorshipType 30 /api/authorshiptype/30 Collaborative Organization -29 true -29 true false true PersonAuthorship 103251811 /api/authorship/103251811 Krenács, T [Krenács, Tibor (Sejtbiológia, imm...), Collaborator] Patológiai és Kísérleti Rákkutató Intézet (SU / FM / I) 15 0.0 false false Author 10007878 /api/author/10007878 Tibor Krenács (Sejtbiológia, immunológia, pathológia) Krenács Tibor true 10007878 true Krenács T false false true AuthorshipType 12 /api/authorshiptype/12 Collaborator -11 true -11 true false true PersonAuthorship 103251824 /api/authorship/103251824 Kulka, J [Kulka, Janina (Emlőpathológia), Collaborator] Patológiai, Igazságügyi és Biztosítási Orvostan... (SU / FM / I) 16 0.0 false false Author 10017900 /api/author/10017900 Janina Kulka (Emlőpathológia) Kulka Janina true 10017900 true Kulka J false false true AuthorshipType 12 /api/authorshiptype/12 Collaborator -11 true -11 true false true PersonAuthorship 103251825 /api/authorship/103251825 Dank, M [Collaborator] 17 0.0 false false Dank M false false true AuthorshipType 12 /api/authorshiptype/12 Collaborator -11 true -11 true false true PersonAuthorship 103251826 /api/authorship/103251826 Polgár, C [Polgár, Csaba (Sugárterápia, kli...), Collaborator] National Institute of Oncology; Onkológiai Tanszék (SU / FM / C) 18 0.0 false false Author 10013383 /api/author/10013383 Csaba Polgár (Sugárterápia, klinikai onkológia) Polgár Csaba true 10013383 true Polgár C false false true AuthorshipType 12 /api/authorshiptype/12 Collaborator -11 true -11 true false true PersonAuthorship 103251827 /api/authorship/103251827 Kapitány, Z [Kapitány, Zsuzsanna (Emésztőrendszeri ...), Collaborator] Department of Physiotherapy (SU / FHS) 19 0.0 false false Author 10023482 /api/author/10023482 Zsuzsanna Kapitány (Emésztőrendszeri daganatos betegek fizioterápiás ellátása, rehabilitációja) Kapitány Zsuzsanna true 10023482 true Kapitány Z false false true AuthorshipType 12 /api/authorshiptype/12 Collaborator -11 true -11 true false true PersonAuthorship 103251828 /api/authorship/103251828 Koncz, Z [Koncz, Zsuzsa (klinikai szakpszi...), Collaborator] Department of Behavioral Sciences (SU / FM / I) 20 0.0 false false Author 10067729 /api/author/10067729 Zsuzsa Koncz (klinikai szakpszichológus) Koncz Zsuzsa true true Koncz Z false false true AuthorshipType 12 /api/authorshiptype/12 Collaborator -11 true -11 true false true PublicationIdentifier 21314002 /api/publicationidentifier/21314002 DOI: 10.3389/pore.2022.1610383 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.3389/pore.2022.1610383 https://doi.org/10.3389/pore.2022.1610383 false true PublicationIdentifier 21616417 /api/publicationidentifier/21616417 WoS: 000831832300001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000831832300001 https://www.webofscience.com/wos/woscc/full-record/000831832300001 false true PublicationIdentifier 21623011 /api/publicationidentifier/21623011 Scopus: 85133540628 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85133540628 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85133540628 true true PublicationIdentifier 21509556 /api/publicationidentifier/21509556 PubMed: 35898593 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 35898593 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35898593&dopt=Abstract false true PublicationIdentifier 29757776 /api/publicationidentifier/29757776 SZTE Publicatio: 37582 SwordSource 90 /api/publicationsource/90 SZTE Publicatio PublicationSourceType 10007 /api/publicationsourcetype/10007 Repozitórium true true true SZTE Publicatio SZTE Publicatio http://publicatio.bibl.u-szeged.hu/@@@ true true 90 true GREEN true IDENTICAL 37582 http://publicatio.bibl.u-szeged.hu/37582 false true Classification 12215 /api/classification/12215 Clinical medicine true true Classification 12306 /api/classification/12306 Oncology true true SjrRating 11309965 /api/sjrrating/11309965 sjr:Q2 (2022) Scopus - Medicine (miscellaneous) PATHOLOGY AND ONCOLOGY RESEARCH 1219-4956 1532-2807 977 0.49 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2701 /api/classificationexternal/2701 Scopus - Medicine (miscellaneous) true 2701 true Q2 DIRECT true true Reference 32203156 /api/reference/32203156 1. Horváth 2016: Systemic Therapy of Breast Cancer: Practice Guideline., Magy Onkol, 60, p. 241 1 false true Reference 32203157 /api/reference/32203157 2. Cardoso 2019: Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up., Ann Oncol, 30, p. 1194, DOI: 10.1093/annonc/mdz173 2 10.1093/annonc/mdz173 false true Reference 32203158 /api/reference/32203158 3. : NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)): Breast Cancer: NCCN.Org; 2020 3 false true Reference 32203159 /api/reference/32203159 4. Cardoso 2020: 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5)., Ann Oncol, 31, p. 1623, DOI: 10.1016/j.annonc.2020.09.010 4 10.1016/j.annonc.2020.09.010 false true Reference 32203160 /api/reference/32203160 5. Burstein 2019: Estimating the Benefits of Therapy for Early-Stage Breast Cancer: the St. Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019., Ann Oncol, 30, p. 1541, DOI: 10.1093/annonc/mdz235 5 10.1093/annonc/mdz235 false true Reference 32203161 /api/reference/32203161 6. Wilson 2013: The Requirements of a Specialist Breast Centre., Eur J Cancer, 49, p. 3579, DOI: 10.1016/j.ejca.2013.07.017 6 10.1016/j.ejca.2013.07.017 false true Reference 32203162 /api/reference/32203162 7. Pons-Tostivint 2019: Multidisciplinary Team Meeting and EUSOMA Quality Indicators in Breast Cancer Care: A French Regional Multicenter Study., The Breast, 46, p. 170, DOI: 10.1016/j.breast.2019.06.001 7 10.1016/j.breast.2019.06.001 false true Reference 32203163 /api/reference/32203163 8. Hammond 2010: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer., Jco, 28, p. 2784, DOI: 10.1200/jco.2009.25.6529 8 10.1200/jco.2009.25.6529 false true Reference 32203164 /api/reference/32203164 9. Yi 2014: Which Threshold for ER Positivity? a Retrospective Study Based on 9639 Patients., Ann Oncol, 25, p. 1004, DOI: 10.1093/annonc/mdu053 9 10.1093/annonc/mdu053 false true Reference 32203165 /api/reference/32203165 10. Giannakeas 2020: Single Hormone Receptor-Positive Breast Cancer-Signal or Noise?., JAMA Netw Open, 3, p. e1918176, DOI: 10.1001/jamanetworkopen.2019.18176 10 10.1001/jamanetworkopen.2019.18176 false true Reference 32203166 /api/reference/32203166 11. Giuliano 2018: Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer., Ann Surg Oncol, 25, p. 1783, DOI: 10.1245/s10434-018-6486-6 11 10.1245/s10434-018-6486-6 false true Reference 32203167 /api/reference/32203167 12. Margolese 2016: Anastrozole versus Tamoxifen in Postmenopausal Women with Ductal Carcinoma In Situ Undergoing Lumpectomy Plus Radiotherapy (NSABP B-35): a Randomised, Double-Blind, Phase 3 Clinical Trial., The Lancet, 387, p. 849, DOI: 10.1016/s0140-6736(15)01168-x 12 10.1016/s0140-6736(15)01168-x false true Reference 32203168 /api/reference/32203168 13. Narod 2015: Breast Cancer Mortality after a Diagnosis of Ductal Carcinoma In Situ., JAMA Oncol, 1, p. 888, DOI: 10.1001/jamaoncol.2015.2510 13 10.1001/jamaoncol.2015.2510 false true Reference 32203169 /api/reference/32203169 14. Phung 2019: Prognostic Models for Breast Cancer: a Systematic Review., BMC cancer, 19, p. 230, DOI: 10.1186/s12885-019-5442-6 14 10.1186/s12885-019-5442-6 false true Reference 32203170 /api/reference/32203170 15. Gray 2018: Survival Estimates Stratified by the Nottingham Prognostic Index for Early Breast Cancer: a Systematic Review and Meta-Analysis of Observational Studies., Syst Rev, 7, p. 142, DOI: 10.1186/s13643-018-0803-9 15 10.1186/s13643-018-0803-9 false true Reference 32203171 /api/reference/32203171 16. Hearne 2015: Comparison of Nottingham Prognostic Index and Adjuvant Online Prognostic Tools in Young Women with Breast Cancer: Review of a Single-Institution Experience., BMJ open, 5, p. e005576, DOI: 10.1136/bmjopen-2014-005576 16 10.1136/bmjopen-2014-005576 false true Reference 32203172 /api/reference/32203172 17. Lee 2008: The Nottingham Prognostic index for Invasive Carcinoma of the Breast., Pathol Oncol Res, 14, p. 113, DOI: 10.1007/s12253-008-9067-3 17 10.1007/s12253-008-9067-3 false true Reference 32203173 /api/reference/32203173 18. Harnan 2019: Tumour Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Early Breast Cancer: a Systematic Review and Economic Analysis., Health Technol Assess, 23, p. 1, DOI: 10.3310/hta23300 18 10.3310/hta23300 false true Reference 32203174 /api/reference/32203174 19. Candido Dos Reis 2017: An Updated PREDICT Breast Cancer Prognostication and Treatment Benefit Prediction Model with Independent Validation., Breast Cancer Res, 19, p. 58, DOI: 10.1186/s13058-017-0852-3 19 10.1186/s13058-017-0852-3 false true Reference 32203175 /api/reference/32203175 20. Wishart 2012: PREDICT Plus: Development and Validation of a Prognostic Model for Early Breast Cancer that Includes HER2., Br J Cancer, 107, p. 800, DOI: 10.1038/bjc.2012.338 20 10.1038/bjc.2012.338 false true Reference 32203176 /api/reference/32203176 21. Wishart 2010: PREDICT: a New UK Prognostic Model that Predicts Survival Following Surgery for Invasive Breast Cancer., Breast Cancer Res, 12, p. R1, DOI: 10.1186/bcr2464 21 10.1186/bcr2464 false true Reference 32203177 /api/reference/32203177 22. Sparano 2018: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer., N Engl J Med, 379, p. 111, DOI: 10.1056/nejmoa1804710 22 10.1056/nejmoa1804710 false true Reference 32203178 /api/reference/32203178 23. Paik 2006: Gene Expression and Benefit of Chemotherapy in Women with Node-Negative, Estrogen Receptor-Positive Breast Cancer., Jco, 24, p. 3726, DOI: 10.1200/jco.2005.04.7985 23 10.1200/jco.2005.04.7985 false true Reference 32203179 /api/reference/32203179 24. Massarweh 2018: Molecular Characterization and Mortality from Breast Cancer in Men., Jco, 36, p. 1396, DOI: 10.1200/jco.2017.76.8861 24 10.1200/jco.2017.76.8861 false true Reference 32203180 /api/reference/32203180 25. Sparano 2018: Association of Circulating Tumor Cells with Late Recurrence of Estrogen Receptor-Positive Breast Cancer., JAMA Oncol, 4, p. 1700, DOI: 10.1001/jamaoncol.2018.2574 25 10.1001/jamaoncol.2018.2574 false true Reference 32203181 /api/reference/32203181 26. Hibler 2016: Bone Loss after Oophorectomy Among High-Risk Women: an NRG Oncology/gynecologic Oncology Group Study., Menopause, 23, p. 1228, DOI: 10.1097/gme.0000000000000692 26 10.1097/gme.0000000000000692 false true Reference 32203182 /api/reference/32203182 27. Francis 2018: Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer., N Engl J Med, 379, p. 122, DOI: 10.1056/nejmoa1803164 27 10.1056/nejmoa1803164 false true Reference 32203183 /api/reference/32203183 28. Gibson 2009: Aromatase Inhibitors for Treatment of Advanced Breast Cancer in Postmenopausal Women., Cochrane Database Syst Rev, 2009, p. CD003370, DOI: 10.1002/14651858.CD003370.pub3 28 10.1002/14651858.CD003370.pub3 false true Reference 32203184 /api/reference/32203184 29. Regan 2016: Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials., Jco, 34, p. 2221, DOI: 10.1200/jco.2015.64.3171 29 10.1200/jco.2015.64.3171 false true Reference 32203185 /api/reference/32203185 30. Pagani 2020: Absolute Improvements in Freedom from Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results from TEXT and SOFT., Jco, 38, p. 1293, DOI: 10.1200/jco.18.01967 30 10.1200/jco.18.01967 false true Reference 32203186 /api/reference/32203186 31. Regan 2017: Concurrent and Sequential Initiation of Ovarian Function Suppression with Chemotherapy in Premenopausal Women with Endocrine-Responsive Early Breast Cancer: an Exploratory Analysis of TEXT and SOFT., Ann Oncol, 28, p. 2225, DOI: 10.1093/annonc/mdx285 31 10.1093/annonc/mdx285 false true Reference 32203187 /api/reference/32203187 32. van Hellemond 2018: Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer., Curr Treat Options Oncol, 19, p. 26, DOI: 10.1007/s11864-018-0541-1 32 10.1007/s11864-018-0541-1 false true Reference 32203188 /api/reference/32203188 33. Ribnikar 2017: Extended Adjuvant Endocrine Therapy - A Standard to All or Some?., The Breast, 32, p. 112, DOI: 10.1016/j.breast.2017.01.004 33 10.1016/j.breast.2017.01.004 false true Reference 32203189 /api/reference/32203189 34. Clement 2018: Extended Duration of Adjuvant Aromatase Inhibitor in Breast Cancer: a Meta-Analysis of Randomized Controlled Trials., Gland Surg, 7, p. 449, DOI: 10.21037/gs.2018.08.03 34 10.21037/gs.2018.08.03 false true Reference 32203190 /api/reference/32203190 35. Burstein 2019: Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update., Jco, 37, p. 423, DOI: 10.1200/jco.18.01160 35 10.1200/jco.18.01160 false true Reference 32203191 /api/reference/32203191 36. Gray 2019: Effects of Prolonging Adjuvant Aromatase Inhibitor Therapy beyond Five Years on Recurrence and Cause-specific Mortality: an EBCTCG Meta-Analysis of Individual Patient Data from 12 Randomised Trials Including 24,912 Women., Cancer Res, 79, DOI: 10.1158/1538-7445.SABCS18-GS3-03 36 10.1158/1538-7445.SABCS18-GS3-03 false true Reference 32203192 /api/reference/32203192 37. Kalinsky 2021: 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer., N Engl J Med, 385, p. 2336, DOI: 10.1056/nejmoa2108873 37 10.1056/nejmoa2108873 false true Reference 32203193 /api/reference/32203193 38. LeVasseur 2021: Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients with 1-3 Positive Nodes: A Prospective Clinical Utility Study., Clin Breast Cancer, 22, p. e74, DOI: 10.1016/j.clbc.2021.09.004 38 10.1016/j.clbc.2021.09.004 false true Reference 32203194 /api/reference/32203194 39. Jones 2009: Docetaxel with Cyclophosphamide Is Associated with an Overall Survival Benefit Compared with Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735., Jco, 27, p. 1177, DOI: 10.1200/jco.2008.18.4028 39 10.1200/jco.2008.18.4028 false true Reference 32203195 /api/reference/32203195 40. Fisher 2001: Findings from Recent National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies in Stage I Breast Cancer., JNCI Monogr, 2001, p. 62, DOI: 10.1093/oxfordjournals.jncimonographs.a003463 40 10.1093/oxfordjournals.jncimonographs.a003463 false true Reference 32203196 /api/reference/32203196 41. Early Breast Cancer Trialists' Collaborative 2005: Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-year Survival: an Overview of the Randomised Trials., The Lancet, 365, p. 1687, DOI: 10.1016/s0140-6736(05)66544-0 41 10.1016/s0140-6736(05)66544-0 false true Reference 32203197 /api/reference/32203197 42. Bines 2014: Anthracyclines and Taxanes in the Neo/adjuvant Treatment of Breast Cancer: Does the Sequence Matter?., Ann Oncol, 25, p. 1079, DOI: 10.1093/annonc/mdu007 42 10.1093/annonc/mdu007 false true Reference 32203198 /api/reference/32203198 43. Citron 2003: Randomized Trial of Dose-Dense versus Conventionally Scheduled and Sequential versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741., Jco, 21, p. 1431, DOI: 10.1200/jco.2003.09.081 43 10.1200/jco.2003.09.081 false true Reference 32203199 /api/reference/32203199 44. Sparano 2008: Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer., N Engl J Med, 358, p. 1663, DOI: 10.1056/nejmoa0707056 44 10.1056/nejmoa0707056 false true Reference 32203200 /api/reference/32203200 45. Mackey 2013: Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide in Node-Positive Breast Cancer: 10-year Follow-Up of the Phase 3 Randomised BCIRG 001 Trial., Lancet Oncol, 14, p. 72, DOI: 10.1016/s1470-2045(12)70525-9 45 10.1016/s1470-2045(12)70525-9 false true Reference 32203201 /api/reference/32203201 46. Swain 2013: Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Operable, Node-Positive Breast Cancer: the NSABP B-38 Trial., Jco, 31, p. 3197, DOI: 10.1200/jco.2012.48.1275 46 10.1200/jco.2012.48.1275 false true Reference 32203202 /api/reference/32203202 47. Chen 2019: Adjuvant Gonadotropin-Releasing Hormone Analogues for the Prevention of Chemotherapy-Induced Premature Ovarian Failure in Premenopausal Women., Cochrane Database Syst Rev, 3, p. CD008018, DOI: 10.1002/14651858.CD008018.pub3 47 10.1002/14651858.CD008018.pub3 false true Reference 32203203 /api/reference/32203203 48. Recht 1996: The Sequencing of Chemotherapy and Radiation Therapy after Conservative Surgery for Early-Stage Breast Cancer., N Engl J Med, 334, p. 1356, DOI: 10.1056/nejm199605233342102 48 10.1056/nejm199605233342102 false true Reference 32203204 /api/reference/32203204 49. Hickey 2013: Sequencing of Chemotherapy and Radiotherapy for Early Breast Cancer., Cochrane Database Syst Rev, 2013, p. CD005212, DOI: 10.1002/14651858.CD005212.pub3 49 10.1002/14651858.CD005212.pub3 false true Reference 32203205 /api/reference/32203205 50. Masuda 2017: Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy., N Engl J Med, 376, p. 2147, DOI: 10.1056/nejmoa1612645 50 10.1056/nejmoa1612645 false true Reference 32203206 /api/reference/32203206 51. Schneeweiss 2013: Pertuzumab Plus Trastuzumab in Combination with Standard Neoadjuvant Anthracycline-Containing and Anthracycline-free Chemotherapy Regimens in Patients with HER2-Positive Early Breast Cancer: a Randomized Phase II Cardiac Safety Study (TRYPHAENA)., Ann Oncol, 24, p. 2278, DOI: 10.1093/annonc/mdt182 51 10.1093/annonc/mdt182 false true Reference 32203207 /api/reference/32203207 52. Schneeweiss 2018: Long-term Efficacy Analysis of the Randomised, Phase II TRYPHAENA Cardiac Safety Study: Evaluating Pertuzumab and Trastuzumab Plus Standard Neoadjuvant Anthracycline-Containing and Anthracycline-free Chemotherapy Regimens in Patients with HER2-Positive Early Breast Cancer., Eur J Cancer, 89, p. 27, DOI: 10.1016/j.ejca.2017.10.021 52 10.1016/j.ejca.2017.10.021 false true Reference 32203208 /api/reference/32203208 53. Gianni 2012: Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women with Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (NeoSphere): a Randomised Multicentre, Open-Label, Phase 2 Trial., Lancet Oncol, 13, p. 25, DOI: 10.1016/s1470-2045(11)70336-9 53 10.1016/s1470-2045(11)70336-9 false true Reference 32203209 /api/reference/32203209 54. Gianni 2016: 5-year Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients with Locally Advanced, Inflammatory, or Early-Stage HER2-Positive Breast Cancer (NeoSphere): a Multicentre, Open-Label, Phase 2 Randomised Trial., Lancet Oncol, 17, p. 791, DOI: 10.1016/s1470-2045(16)00163-7 54 10.1016/s1470-2045(16)00163-7 false true Reference 32203210 /api/reference/32203210 55. Harbeck 2021: De-escalated Neoadjuvant Pertuzumab+trastuzumab with or without Paclitaxel Weekly in HR-/HER2+ Early Breast Cancer: ADAPT-HR-/HER2+ Biomarker and Survival Results., Jco, 39, p. 503, DOI: 10.1200/jco.2021.39.15_suppl.503 55 10.1200/jco.2021.39.15_suppl.503 false true Reference 32203211 /api/reference/32203211 56. O'Sullivan 2021: Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/placebo in Patients with Residual HER2-Positive Invasive Breast Cancer., Future Oncol, 17, p. 4665, DOI: 10.2217/fon-2021-0753 56 10.2217/fon-2021-0753 false true Reference 32203212 /api/reference/32203212 57. von Minckwitz 2017: Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer., N Engl J Med, 377, p. 122, DOI: 10.1056/nejmoa1703643 57 10.1056/nejmoa1703643 false true Reference 32203213 /api/reference/32203213 58. von Minckwitz 2019: Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer., N Engl J Med, 380, p. 617, DOI: 10.1056/nejmoa1814017 58 10.1056/nejmoa1814017 false true Reference 32203214 /api/reference/32203214 59. Baselga 2012: Lapatinib with Trastuzumab for HER2-Positive Early Breast Cancer (NeoALTTO): a Randomised, Open-Label, Multicentre, Phase 3 Trial., The Lancet, 379, p. 633, DOI: 10.1016/s0140-6736(11)61847-3 59 10.1016/s0140-6736(11)61847-3 false true Reference 32203215 /api/reference/32203215 60. Tolaney 2019: Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer., Jco, 37, p. 1868, DOI: 10.1200/jco.19.00066 60 10.1200/jco.19.00066 false true Reference 32203216 /api/reference/32203216 61. De Cock 2016: A Time and Motion Study of Subcutaneous versus Intravenous Trastuzumab in Patients with HER2-Positive Early Breast Cancer., Cancer Med, 5, p. 389, DOI: 10.1002/cam4.573 61 10.1002/cam4.573 false true Reference 32203217 /api/reference/32203217 62. Tjalma 2018: Subcutaneous Trastuzumab (Herceptin) versus Intravenous Trastuzumab for the Treatment of Patients with HER2-Positive Breast Cancer: A Time, Motion and Cost Assessment Study in a Lean Operating Day Care Oncology Unit., Eur J Obstet Gynecol Reprod Biol, 221, p. 46, DOI: 10.1016/j.ejogrb.2017.12.006 62 10.1016/j.ejogrb.2017.12.006 false true Reference 32203218 /api/reference/32203218 63. Ismael 2012: Subcutaneous versus Intravenous Administration of (Neo)adjuvant Trastuzumab in Patients with HER2-Positive, Clinical Stage I-III Breast Cancer (HannaH Study): a Phase 3, Open-Label, Multicentre, Randomised Trial., Lancet Oncol, 13, p. 869, DOI: 10.1016/s1470-2045(12)70329-7 63 10.1016/s1470-2045(12)70329-7 false true Reference 32203219 /api/reference/32203219 64. Tadros 2018: Breast Cancers of Special Histologic Subtypes Are Biologically Diverse., Ann Surg Oncol, 25, p. 3158, DOI: 10.1245/s10434-018-6687-z 64 10.1245/s10434-018-6687-z false true Reference 32203220 /api/reference/32203220 65. Martin 2017: Neratinib after Trastuzumab-Based Adjuvant Therapy in HER2-Positive Breast Cancer (ExteNET): 5-year Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial., Lancet Oncol, 18, p. 1688, DOI: 10.1016/S1470-2045(17)30717-9 65 10.1016/S1470-2045(17)30717-9 false true Reference 32203221 /api/reference/32203221 66. Robson 2017: Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N Engl J Med, 377, p. 523, DOI: 10.1056/nejmoa1706450 66 10.1056/nejmoa1706450 false true Reference 32203222 /api/reference/32203222 67. Ellis 2008: Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics., JNCI J Natl Cancer Inst, 100, p. 1380, DOI: 10.1093/jnci/djn309 67 10.1093/jnci/djn309 false true Reference 32203223 /api/reference/32203223 68. Dawood 2011: International Expert Panel on Inflammatory Breast Cancer: Consensus Statement for Standardized Diagnosis and Treatment., Ann Oncol, 22, p. 515, DOI: 10.1093/annonc/mdq345 68 10.1093/annonc/mdq345 false true Reference 32203224 /api/reference/32203224 69. Ueno 2018: International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference., J Cancer, 9, p. 1437, DOI: 10.7150/jca.23969 69 10.7150/jca.23969 false true Reference 32203225 /api/reference/32203225 70. Aebi 2014: Chemotherapy for Isolated Locoregional Recurrence of Breast Cancer (CALOR): a Randomised Trial., Lancet Oncol, 15, p. 156, DOI: 10.1016/s1470-2045(13)70589-8 70 10.1016/s1470-2045(13)70589-8 false true Reference 32203226 /api/reference/32203226 71. Johnston 2020: Abemaciclib Combined with Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)., Jco, 38, p. 3987, DOI: 10.1200/jco.20.02514 71 10.1200/jco.20.02514 false true Reference 32203227 /api/reference/32203227 72. Harbeck 2021: Adjuvant Abemaciclib Combined with Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis from the monarchE Study., Ann Oncol : official J Eur Soc Med Oncol, 32, p. 1571, DOI: 10.1016/j.annonc.2021.09.015 72 10.1016/j.annonc.2021.09.015 false true Reference 32203228 /api/reference/32203228 73. Loibl 2021: Durvalumab Improves Long-Term Outcome in TNBC: Results from the Phase II Randomized GeparNUEVO Study Investigating Neodjuvant Durvalumab in Addition to an Anthracycline/taxane Based Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC)., Jco, 39, p. 506, DOI: 10.1200/jco.2021.39.15_suppl.506 73 10.1200/jco.2021.39.15_suppl.506 false true Reference 32203229 /api/reference/32203229 74. Schmid Jc 2019: KEYNOTE-522: Phase 3 Study of Pembrolizumab (Pembro) + Chemotherapy (Chemo) vs Placebo (Pbo) + Chemo as Neoadjuvant Treatment, Followed by Pembro vs Pbo as Adjuvant Treatment for Early Triple-Negative Breast Cancer (TNBC)., Ann Oncol, 30, p. v851, DOI: 10.1093/annonc/mdz394.003 74 10.1093/annonc/mdz394.003 false true Reference 32203230 /api/reference/32203230 75. Tripathy 2018: Ribociclib Plus Endocrine Therapy for Premenopausal Women with Hormone-Receptor-Positive, Advanced Breast Cancer (MONALEESA-7): a Randomised Phase 3 Trial., Lancet Oncol, 19, p. 904, DOI: 10.1016/s1470-2045(18)30292-4 75 10.1016/s1470-2045(18)30292-4 false true Reference 32203231 /api/reference/32203231 76. Hortobagyi Sms 2021: Overall Survival (OS) Results from the Phase III MONALEESA-2 (ML-2) Trial of Postmenopausal Patients (Pts) with Hormone Receptor Positive/human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Advanced Breast Cancer (ABC) Treated with Endocrine Therapy (ET) ± Ribociclib (RIB)., Ann Oncol, 32, p. 1283, DOI: 10.1016/j.annonc.2021.08.2090 76 10.1016/j.annonc.2021.08.2090 false true Reference 32203232 /api/reference/32203232 77. Finn 2016: Palbociclib and Letrozole in Advanced Breast Cancer., N Engl J Med, 375, p. 1925, DOI: 10.1056/nejmoa1607303 77 10.1056/nejmoa1607303 false true Reference 32203233 /api/reference/32203233 78. Hortobagyi 2016: Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer., N Engl J Med, 375, p. 1738, DOI: 10.1056/nejmoa1609709 78 10.1056/nejmoa1609709 false true Reference 32203234 /api/reference/32203234 79. Hortobagyi 2019: Updated Results from MONALEESA-2, a Phase III Trial of First-Line Ribociclib Plus Letrozole versus Placebo Plus Letrozole in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer., Ann Oncol, 30, p. 1842, DOI: 10.1093/annonc/mdz215 79 10.1093/annonc/mdz215 false true Reference 32203235 /api/reference/32203235 80. Goetz 2017: MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer., Jco, 35, p. 3638, DOI: 10.1200/jco.2017.75.6155 80 10.1200/jco.2017.75.6155 false true Reference 32203236 /api/reference/32203236 81. Turner 2018: Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer., N Engl J Med, 379, p. 1926, DOI: 10.1056/nejmoa1810527 81 10.1056/nejmoa1810527 false true Reference 32203237 /api/reference/32203237 82. Cristofanilli 2016: Fulvestrant Plus Palbociclib versus Fulvestrant Plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer that Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial., Lancet Oncol, 17, p. 425, DOI: 10.1016/s1470-2045(15)00613-0 82 10.1016/s1470-2045(15)00613-0 false true Reference 32203238 /api/reference/32203238 83. Slamon 2021: Ribociclib Plus Fulvestrant for Postmenopausal Women with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in the Phase III Randomized MONALEESA-3 Trial: Updated Overall Survival., Ann Oncol, 32, p. 1015, DOI: 10.1016/j.annonc.2021.05.353 83 10.1016/j.annonc.2021.05.353 false true Reference 32203239 /api/reference/32203239 84. Slamon 2020: Overall Survival with Ribociclib Plus Fulvestrant in Advanced Breast Cancer., N Engl J Med, 382, p. 514, DOI: 10.1056/nejmoa1911149 84 10.1056/nejmoa1911149 false true Reference 32203240 /api/reference/32203240 85. Slamon 2018: Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3., Jco, 36, p. 2465, DOI: 10.1200/jco.2018.78.9909 85 10.1200/jco.2018.78.9909 false true Reference 32203241 /api/reference/32203241 86. Sledge 2017: MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women with HR+/HER2− Advanced Breast Cancer Who Had Progressed while Receiving Endocrine Therapy., Jco, 35, p. 2875, DOI: 10.1200/jco.2017.73.7585 86 10.1200/jco.2017.73.7585 false true Reference 32203242 /api/reference/32203242 87. Sledge 2020: The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer that Progressed on Endocrine Therapy-MONARCH 2., JAMA Oncol, 6, p. 116, DOI: 10.1001/jamaoncol.2019.4782 87 10.1001/jamaoncol.2019.4782 false true Reference 32203243 /api/reference/32203243 88. O'Shaughnessy 2018: Ribociclib Plus Letrozole versus Letrozole Alone in Patients with De Novo HR+, HER2- Advanced Breast Cancer in the Randomized MONALEESA-2 Trial., Breast Cancer Res Treat, 168, p. 127, DOI: 10.1007/s10549-017-4518-8 88 10.1007/s10549-017-4518-8 false true Reference 32203244 /api/reference/32203244 89. Kaufman 2020: Health-Related Quality of Life in MONARCH 2: Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer after Endocrine Therapy., The oncologist, 25, p. e243, DOI: 10.1634/theoncologist.2019-0551 89 10.1634/theoncologist.2019-0551 false true Reference 32203245 /api/reference/32203245 90. Turner 2015: Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer., N Engl J Med, 373, p. 209, DOI: 10.1056/nejmoa1505270 90 10.1056/nejmoa1505270 false true Reference 32203246 /api/reference/32203246 91. Baselga 2012: Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer., N Engl J Med, 366, p. 520, DOI: 10.1056/nejmoa1109653 91 10.1056/nejmoa1109653 false true Reference 32203247 /api/reference/32203247 92. Im 2019: Overall Survival with Ribociclib Plus Endocrine Therapy in Breast Cancer., N Engl J Med, 381, p. 307, DOI: 10.1056/nejmoa1903765 92 10.1056/nejmoa1903765 false true Reference 32203248 /api/reference/32203248 93. Sledge 2020: The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer that Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial., JAMA Oncol, 6, p. 116, DOI: 10.1001/jamaoncol.2019.4782 93 10.1001/jamaoncol.2019.4782 false true Reference 32203249 /api/reference/32203249 94. Spring 2019: CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions., Curr Oncol Rep, 21, p. 25, DOI: 10.1007/s11912-019-0769-3 94 10.1007/s11912-019-0769-3 false true Reference 32203250 /api/reference/32203250 95. Piccart 2014: Everolimus Plus Exemestane for Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Overall Survival Results from BOLERO-2., Ann Oncol, 25, p. 2357, DOI: 10.1093/annonc/mdu456 95 10.1093/annonc/mdu456 false true Reference 32203251 /api/reference/32203251 96. Bachelot 2012: Randomized Phase II Trial of Everolimus in Combination with Tamoxifen in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer with Prior Exposure to Aromatase Inhibitors: a GINECO Study., Jco, 30, p. 2718, DOI: 10.1200/jco.2011.39.0708 96 10.1200/jco.2011.39.0708 false true Reference 32203252 /api/reference/32203252 97. Massarweh 2014: A Phase II Study of Combined Fulvestrant and Everolimus in Patients with Metastatic Estrogen Receptor (ER)-positive Breast Cancer after Aromatase Inhibitor (AI) Failure., Breast Cancer Res Treat, 143, p. 325, DOI: 10.1007/s10549-013-2810-9 97 10.1007/s10549-013-2810-9 false true Reference 32203253 /api/reference/32203253 98. Mehta 2012: Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer., N Engl J Med, 367, p. 435, DOI: 10.1056/nejmoa1201622 98 10.1056/nejmoa1201622 false true Reference 32203254 /api/reference/32203254 99. Dickler 2017: MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer., Clin Cancer Res, 23, p. 5218, DOI: 10.1158/1078-0432.ccr-17-0754 99 10.1158/1078-0432.ccr-17-0754 false true Reference 32203255 /api/reference/32203255 100. André 2019: Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer., N Engl J Med, 380, p. 1929, DOI: 10.1056/nejmoa1813904 100 10.1056/nejmoa1813904 false true Reference 32203256 /api/reference/32203256 101. Kaufman 2009: Trastuzumab Plus Anastrozole versus Anastrozole Alone for the Treatment of Postmenopausal Women with Human Epidermal Growth Factor Receptor 2-positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results from the Randomized Phase III TAnDEM Study., Jco, 27, p. 5529, DOI: 10.1200/jco.2008.20.6847 101 10.1200/jco.2008.20.6847 false true Reference 32203257 /api/reference/32203257 102. Johnston 2009: Lapatinib Combined with Letrozole versus Letrozole and Placebo as First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer., Jco, 27, p. 5538, DOI: 10.1200/jco.2009.23.3734 102 10.1200/jco.2009.23.3734 false true Reference 32203258 /api/reference/32203258 103. Schwartzberg 2010: Lapatinib Plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer., The oncologist, 15, p. 122, DOI: 10.1634/theoncologist.2009-0240 103 10.1634/theoncologist.2009-0240 false true Reference 32203259 /api/reference/32203259 104. Liu 2017: The Efficacy and Toxicity Profile of Metronomic Chemotherapy for Metastatic Breast Cancer: A Meta-Analysis., PloS one, 12, p. e0173693, DOI: 10.1371/journal.pone.0173693 104 10.1371/journal.pone.0173693 false true Reference 32203260 /api/reference/32203260 105. Cazzaniga 2016: Metronomic Chemotherapy with Oral Vinorelbine (mVNR) and Capecitabine (mCAPE) in Advanced HER2-Negative Breast Cancer Patients: Is it a Way to Optimize Disease Control? Final Results of the VICTOR-2 Study., Breast Cancer Res Treat, 160, p. 501, DOI: 10.1007/s10549-016-4009-3 105 10.1007/s10549-016-4009-3 false true Reference 32203261 /api/reference/32203261 106. Fedele 2012: Efficacy and Safety of Low-Dose Metronomic Chemotherapy with Capecitabine in Heavily Pretreated Patients with Metastatic Breast Cancer., Eur J Cancer, 48, p. 24, DOI: 10.1016/j.ejca.2011.06.040 106 10.1016/j.ejca.2011.06.040 false true Reference 32203262 /api/reference/32203262 107. Li 2015: Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials., Sci Rep, 5, p. 15746, DOI: 10.1038/srep15746 107 10.1038/srep15746 false true Reference 32203263 /api/reference/32203263 108. Tutt 2018: Carboplatin in BRCA1/2-Mutated and Triple-Negative Breast Cancer BRCAness Subgroups: the TNT Trial., Nat Med, 24, p. 628, DOI: 10.1038/s41591-018-0009-7 108 10.1038/s41591-018-0009-7 false true Reference 32203264 /api/reference/32203264 109. Smyth 2016: Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Overexpressing Metastatic Breast Cancer: Overall Survival and Updated Progression-free Survival Results from a Phase II Study., Breast Cancer Res Treat, 158, p. 91, DOI: 10.1007/s10549-016-3851-7 109 10.1007/s10549-016-3851-7 false true Reference 32203265 /api/reference/32203265 110. Swain 2015: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer., N Engl J Med, 372, p. 724, DOI: 10.1056/nejmoa1413513 110 10.1056/nejmoa1413513 false true Reference 32203266 /api/reference/32203266 111. Burstein 2007: Trastuzumab Plus Vinorelbine or Taxane Chemotherapy for HER2-Overexpressing Metastatic Breast Cancer: the Trastuzumab and Vinorelbine or Taxane Study., Cancer, 110, p. 965, DOI: 10.1002/cncr.22885 111 10.1002/cncr.22885 false true Reference 32203267 /api/reference/32203267 112. Robert 2006: Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared with Trastuzumab and Paclitaxel in Women with HER-2-Overexpressing Metastatic Breast Cancer., Jco, 24, p. 2786, DOI: 10.1200/jco.2005.04.1764 112 10.1200/jco.2005.04.1764 false true Reference 32203268 /api/reference/32203268 113. Bartsch 2007: Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer., Jco, 25, p. 3853, DOI: 10.1200/jco.2007.11.9776 113 10.1200/jco.2007.11.9776 false true Reference 32203269 /api/reference/32203269 114. Schaller 2007: Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines or Taxanes., Jco, 25, p. 3246, DOI: 10.1200/jco.2006.09.6826 114 10.1200/jco.2006.09.6826 false true Reference 32203270 /api/reference/32203270 115. Huober 2012: Higher Efficacy of Letrozole in Combination with Trastuzumab Compared to Letrozole Monotherapy as First-Line Treatment in Patients with HER2-Positive, Hormone-Receptor-Positive Metastatic Breast Cancer - Results of the eLEcTRA Trial., The Breast, 21, p. 27, DOI: 10.1016/j.breast.2011.07.006 115 10.1016/j.breast.2011.07.006 false true Reference 32203271 /api/reference/32203271 116. Rimawi 2018: First-Line Trastuzumab Plus an Aromatase Inhibitor, with or without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial., Jco, 36, p. 2826, DOI: 10.1200/jco.2017.76.7863 116 10.1200/jco.2017.76.7863 false true Reference 32203272 /api/reference/32203272 117. Diéras 2017: Trastuzumab Emtansine versus Capecitabine Plus Lapatinib in Patients with Previously Treated HER2-Positive Advanced Breast Cancer (EMILIA): a Descriptive Analysis of Final Overall Survival Results from a Randomised, Open-Label, Phase 3 Trial., Lancet Oncol, 18, p. 732, DOI: 10.1016/s1470-2045(17)30312-1 117 10.1016/s1470-2045(17)30312-1 false true Reference 32203273 /api/reference/32203273 118. Johnston 2018: Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade with Lapatinib Plus Trastuzumab in Combination with an Aromatase Inhibitor in Postmenopausal Women with HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE., Jco, 36, p. 741, DOI: 10.1200/jco.2017.74.7824 118 10.1200/jco.2017.74.7824 false true Reference 32203274 /api/reference/32203274 119. Cameron 2010: Lapatinib Plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial., The oncologist, 15, p. 924, DOI: 10.1634/theoncologist.2009-0181 119 10.1634/theoncologist.2009-0181 false true Reference 32203275 /api/reference/32203275 120. Geyer 2006: Lapatinib Plus Capecitabine for HER2-Positive Advanced Breast Cancer., N Engl J Med, 355, p. 2733, DOI: 10.1056/nejmoa064320 120 10.1056/nejmoa064320 false true Reference 32203276 /api/reference/32203276 121. Verma 2012: Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer., N Engl J Med, 367, p. 1783, DOI: 10.1056/nejmoa1209124 121 10.1056/nejmoa1209124 false true Reference 32203277 /api/reference/32203277 122. Cortés 2021: Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) with HER2+ Metastatic Breast Cancer (mBC): Results of the Randomized Phase III DESTINY-Breast03 Study., Ann Oncol, 32, p. S1283, DOI: 10.1016/j.annonc.2021.08.2087 122 10.1016/j.annonc.2021.08.2087 false true Reference 32203278 /api/reference/32203278 123. Baez-Vallecillo 2019: Lapatinib Activity in Metastatic Human Epidermal Growth Factor Receptor 2-positive Breast Cancers that Received Prior Therapy with Trastuzumab, Pertuzumab, And/or Ado-Trastuzumab Emtansine (T-DM1)., Breast Cancer Res Treat, 176, p. 227, DOI: 10.1007/s10549-018-05081-z 123 10.1007/s10549-018-05081-z false true Reference 32203279 /api/reference/32203279 124. Blackwell 2012: Overall Survival Benefit with Lapatinib in Combination with Trastuzumab for Patients with Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer: Final Results from the EGF104900 Study., Jco, 30, p. 2585, DOI: 10.1200/jco.2011.35.6725 124 10.1200/jco.2011.35.6725 false true Reference 32203280 /api/reference/32203280 125. Krop 2014: Trastuzumab Emtansine versus Treatment of Physician's Choice for Pretreated HER2-Positive Advanced Breast Cancer (TH3RESA): a Randomised, Open-Label, Phase 3 Trial., Lancet Oncol, 15, p. 689, DOI: 10.1016/s1470-2045(14)70178-0 125 10.1016/s1470-2045(14)70178-0 false true Reference 32203281 /api/reference/32203281 126. Krop 2017: Trastuzumab Emtansine versus Treatment of Physician's Choice in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results from a Randomised Open-Label Phase 3 Trial., Lancet Oncol, 18, p. 743, DOI: 10.1016/s1470-2045(17)30313-3 126 10.1016/s1470-2045(17)30313-3 false true Reference 32203282 /api/reference/32203282 127. Blackwell 2010: Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer., Jco, 28, p. 1124, DOI: 10.1200/jco.2008.21.4437 127 10.1200/jco.2008.21.4437 false true Reference 32203283 /api/reference/32203283 128. Curigliano 2022: Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis., Ann Oncol : official J Eur Soc Med Oncol, 33, p. 321, DOI: 10.1016/j.annonc.2021.12.005 128 10.1016/j.annonc.2021.12.005 false true Reference 32203284 /api/reference/32203284 129. Murthy 2020: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer., N Engl J Med, 382, p. 597, DOI: 10.1056/nejmoa1914609 129 10.1056/nejmoa1914609 false true Reference 32203285 /api/reference/32203285 130. Modi 2020: Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer., N Engl J Med, 382, p. 610, DOI: 10.1056/nejmoa1914510 130 10.1056/nejmoa1914510 false true Reference 32203286 /api/reference/32203286 131. Saura 2020: Neratinib Plus Capecitabine versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated with ≥ 2 HER2-Directed Regimens: Phase III NALA Trial., Jco, 38, p. 3138, DOI: 10.1200/jco.20.00147 131 10.1200/jco.20.00147 false true Reference 32203287 /api/reference/32203287 132. Tarantino 2021: Margetuximab for the Treatment of HER2-Positive Metastatic Breast Cancer., Expert Opin Biol Ther, 21, p. 127, DOI: 10.1080/14712598.2021.1856812 132 10.1080/14712598.2021.1856812 false true Reference 32203288 /api/reference/32203288 133. Winer 2021: Pembrolizumab versus Investigator-Choice Chemotherapy for Metastatic Triple-Negative Breast Cancer (KEYNOTE-119): a Randomised, Open-Label, Phase 3 Trial., Lancet Oncol, 22, p. 499, DOI: 10.1016/s1470-2045(20)30754-3 133 10.1016/s1470-2045(20)30754-3 false true Reference 32203289 /api/reference/32203289 134. Schmid 2020: Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (IMpassion130): Updated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial., Lancet Oncol, 21, p. 44, DOI: 10.1016/s1470-2045(19)30689-8 134 10.1016/s1470-2045(19)30689-8 false true Reference 32203290 /api/reference/32203290 135. Emens 2021: First-line Atezolizumab Plus Nab-Paclitaxel for Unresectable, Locally Advanced, or Metastatic Triple-Negative Breast Cancer: IMpassion130 Final Overall Survival Analysis., Ann Oncol, 32, p. 983, DOI: 10.1016/j.annonc.2021.05.355 135 10.1016/j.annonc.2021.05.355 false true Reference 32203291 /api/reference/32203291 136. Miles 2021: Primary Results from IMpassion131, a Double-Blind, Placebo-Controlled, Randomised Phase III Trial of First-Line Paclitaxel with or without Atezolizumab for Unresectable Locally Advanced/metastatic Triple-Negative Breast Cancer., Ann Oncol, 32, p. 994, DOI: 10.1016/j.annonc.2021.05.801 136 10.1016/j.annonc.2021.05.801 false true Reference 32203292 /api/reference/32203292 137. Rugo Jc 2021: KEYNOTE-355: Final Results from a Randomized, Double-Blind Phase III Study of First-Line Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for Metastatic TNBC., Ann Oncol, 32, p. S1283 137 false true Reference 32203293 /api/reference/32203293 138. Coleman 2020: Bone Health in Cancer: ESMO Clinical Practice Guidelines., Ann Oncol, 31, p. 1650, DOI: 10.1016/j.annonc.2020.07.019 138 10.1016/j.annonc.2020.07.019 false true Reference 32203294 /api/reference/32203294 139. Early Breast Cancer Trialists' Collaborative 2015: Adjuvant Bisphosphonate Treatment in Early Breast Cancer: Meta-Analyses of Individual Patient Data from Randomised Trials., The Lancet, 386, p. 1353, DOI: 10.1016/s0140-6736(15)60908-4 139 10.1016/s0140-6736(15)60908-4 false true Reference 32203295 /api/reference/32203295 140. Hadji 2017: Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in Postmenopausal Women with Hormone Sensitive Breast Cancer: Joint Position Statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG., J bone Oncol, 7, p. 1, DOI: 10.1016/j.jbo.2017.03.001 140 10.1016/j.jbo.2017.03.001 false true Reference 32203296 /api/reference/32203296 141. Coleman 2020: Adjuvant Denosumab in Early Breast Cancer (D-CARE): an International, Multicentre, Randomised, Controlled, Phase 3 Trial., Lancet Oncol, 21, p. 60, DOI: 10.1016/s1470-2045(19)30687-4 141 10.1016/s1470-2045(19)30687-4 false true Reference 32203297 /api/reference/32203297 142. Brufsky 2020: Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter?., J Natl Cancer Inst, 112, p. 659, DOI: 10.1093/jnci/djz216 142 10.1093/jnci/djz216 false true Reference 32203298 /api/reference/32203298 143. Byrski 2014: Pathologic Complete Response to Neoadjuvant Cisplatin in BRCA1-Positive Breast Cancer Patients., Breast Cancer Res Treat, 147, p. 401, DOI: 10.1007/s10549-014-3100-x 143 10.1007/s10549-014-3100-x false true Reference 32203299 /api/reference/32203299 144. Zimmer 2018: Update on PARP Inhibitors in Breast Cancer., Curr Treat Options Oncol, 19, p. 21, DOI: 10.1007/s11864-018-0540-2 144 10.1007/s11864-018-0540-2 false true Reference 32203300 /api/reference/32203300 145. Tutt 2021: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer., N Engl J Med, 384, p. 2394, DOI: 10.1056/nejmoa2105215 145 10.1056/nejmoa2105215 false true Reference 32203301 /api/reference/32203301 146. Sonnenblick 2015: An Update on PARP Inhibitors-Moving to the Adjuvant Setting., Nat Rev Clin Oncol, 12, p. 27, DOI: 10.1038/nrclinonc.2014.163 146 10.1038/nrclinonc.2014.163 false true Reference 32203302 /api/reference/32203302 147. Matulonis 2016: Olaparib Monotherapy in Patients with Advanced Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation: a Multistudy Analysis of Response Rates and Safety., Ann Oncol, 27, p. 1013, DOI: 10.1093/annonc/mdw133 147 10.1093/annonc/mdw133 false true Reference 32203303 /api/reference/32203303 148. Gelmon 2011: Olaparib in Patients with Recurrent High-Grade Serous or Poorly Differentiated Ovarian Carcinoma or Triple-Negative Breast Cancer: a Phase 2, Multicentre, Open-Label, Non-randomised Study., Lancet Oncol, 12, p. 852, DOI: 10.1016/s1470-2045(11)70214-5 148 10.1016/s1470-2045(11)70214-5 false true Reference 32203304 /api/reference/32203304 149. Deb 2016: The Cancer Genetics and Pathology of Male Breast Cancer., Histopathology, 68, p. 110, DOI: 10.1111/his.12862 149 10.1111/his.12862 false true Reference 32203305 /api/reference/32203305 150. Johansson 2013: The Landscape of Candidate Driver Genes Differs between Male and Female Breast Cancer., PloS one, 8, p. e78299, DOI: 10.1371/journal.pone.0078299 150 10.1371/journal.pone.0078299 false true Reference 32203306 /api/reference/32203306 151. Ottini 2010: Male Breast Cancer., Crit Rev oncology/hematology, 73, p. 141, DOI: 10.1016/j.critrevonc.2009.04.003 151 10.1016/j.critrevonc.2009.04.003 false true Reference 32203307 /api/reference/32203307 152. Eggemann 2013: Adjuvant Therapy with Tamoxifen Compared to Aromatase Inhibitors for 257 Male Breast Cancer Patients., Breast Cancer Res Treat, 137, p. 465, DOI: 10.1007/s10549-012-2355-3 152 10.1007/s10549-012-2355-3 false true Reference 32203308 /api/reference/32203308 153. Korde 2010: Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations., Jco, 28, p. 2114, DOI: 10.1200/jco.2009.25.5729 153 10.1200/jco.2009.25.5729 false true Reference 32203309 /api/reference/32203309 154. Sousa 2013: An Update on Male Breast Cancer and Future Directions for Research and Treatment., Eur J Pharmacol, 717, p. 71, DOI: 10.1016/j.ejphar.2013.03.037 154 10.1016/j.ejphar.2013.03.037 false true Reference 32203310 /api/reference/32203310 155. Cardoso 2018: Characterization of Male Breast Cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program., Ann Oncol, 29, p. 405, DOI: 10.1093/annonc/mdx651 155 10.1093/annonc/mdx651 false true Reference 32203311 /api/reference/32203311 156. Gucalp 2019: Male Breast Cancer: a Disease Distinct from Female Breast Cancer., Breast Cancer Res Treat, 173, p. 37, DOI: 10.1007/s10549-018-4921-9 156 10.1007/s10549-018-4921-9 false true Reference 32203312 /api/reference/32203312 157. Davies 2013: Long-term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years after Diagnosis of Oestrogen Receptor-Positive Breast Cancer: ATLAS, a Randomised Trial., The Lancet, 381, p. 805, DOI: 10.1016/s0140-6736(12)61963-1 157 10.1016/s0140-6736(12)61963-1 false true Reference 32203313 /api/reference/32203313 158. Rodriguez 2008: Evidence of Poorer Survival in Pregnancy-Associated Breast Cancer., Obstet Gynecol, 112, p. 71, DOI: 10.1097/aog.0b013e31817c4ebc 158 10.1097/aog.0b013e31817c4ebc false true Reference 32203314 /api/reference/32203314 159. Zubor 2018: Current Approaches in the Clinical Management of Pregnancy-Associated Breast Cancer-Pros and Cons., EPMA J, 9, p. 257, DOI: 10.1007/s13167-018-0139-5 159 10.1007/s13167-018-0139-5 false true Reference 32203315 /api/reference/32203315 160. Bandoli 2017: A Review of Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth Outcomes., Rheum Dis Clin North America, 43, p. 489, DOI: 10.1016/j.rdc.2017.04.013 160 10.1016/j.rdc.2017.04.013 false true Reference 32203316 /api/reference/32203316 161. Yu 2017: Current Management of Pregnancy-Associated Breast Cancer., Hong Kong Med J, 23, p. 387, DOI: 10.12809/hkmj166049 161 10.12809/hkmj166049 false true Reference 32203317 /api/reference/32203317 162. Goldhirsch 2013: Personalizing the Treatment of Women with Early Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013., Ann Oncol, 24, p. 2206, DOI: 10.1093/annonc/mdt303 162 10.1093/annonc/mdt303 false true Reference 32203318 /api/reference/32203318 163. Goldhirsch 2007: Progress and Promise: Highlights of the International Expert Consensus on the Primary Therapy of Early Breast Cancer 2007., Ann Oncol, 18, p. 1133, DOI: 10.1093/annonc/mdm271 163 10.1093/annonc/mdm271 false true Reference 32203319 /api/reference/32203319 164. Harlow 2012: Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging., J Clin Endocrinol Metab, 97, p. 1159, DOI: 10.1210/jc.2011-3362 164 10.1210/jc.2011-3362 false true /api/publication/32946435 Rubovszky Gábor et al. Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. (2022) PATHOLOGY AND ONCOLOGY RESEARCH 1219-4956 1532-2807 28<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10060070"><a href="/gui2/?type=authors&mode=browse&sel=10060070" target="_blank">Rubovszky Gábor ✉ (<span class="authorship-author-name">Rubovszky Gábor</span> <span class="authorAux-mtmt"> klinikai onkológia</span>) </a> </span> <span class="author-affil">National Institute of Oncology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Kocsis Judit^* </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10048974"><a href="/gui2/?type=authors&mode=browse&sel=10048974" target="_blank">Boér Katalin (<span class="authorship-author-name">Boér Katalin</span> <span class="authorAux-mtmt"> Klinikai Orvostudomány</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Chilingirova Nataliya </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10011481"><a href="/gui2/?type=authors&mode=browse&sel=10011481" target="_blank">Dank Magdolna (<span class="authorship-author-name">Dank Magdolna</span> <span class="authorAux-mtmt"> onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Department of Internal Medicine and Oncology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10013805"><a href="/gui2/?type=authors&mode=browse&sel=10013805" target="_blank">Kahán Zsuzsanna (<span class="authorship-author-name">Kahán Zsuzsanna</span> <span class="authorAux-mtmt"> Elméleti orvostudomány</span>) </a> </span> <span class="author-affil"><span title="University of Szeged">SZTE</span>/<span title="Albert Szent-Györgyi Medical School">ASZMS</span>/Department of Oncotherapy</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Kaidarova Dilyara </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10025719"><a href="/gui2/?type=authors&mode=browse&sel=10025719" target="_blank">Kövér Erika (<span class="authorship-author-name">Kövér Erika</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil"><span title="University of Pécs">UP</span>/<span title="Medical School">UPMS</span>/Department of Oncotherapy</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Krakovská Bibiana Vertáková </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10035708"><a href="/gui2/?type=authors&mode=browse&sel=10035708" target="_blank">Máhr Károly (<span class="authorship-author-name">Máhr Károly</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Mriňáková Bela </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Pikó Béla </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Božović-Spasojević Ivana </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10026959"><a href="/gui2/?type=authors&mode=browse&sel=10026959" target="_blank">Horváth Zsolt (<span class="authorship-author-name">Horváth Zsolt</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> </div> <div class="autype autype-11"> Collaborator: <span class="author-name" mtid="10007878"><a href="/gui2/?type=authors&mode=browse&sel=10007878" target="_blank">Krenács T (<span class="authorship-author-name">Krenács Tibor</span> <span class="authorAux-mtmt"> Sejtbiológia, immunológia, pathológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10017900"><a href="/gui2/?type=authors&mode=browse&sel=10017900" target="_blank">Kulka J (<span class="authorship-author-name">Kulka Janina</span> <span class="authorAux-mtmt"> Emlőpathológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Dank M </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10013383"><a href="/gui2/?type=authors&mode=browse&sel=10013383" target="_blank">Polgár C (<span class="authorship-author-name">Polgár Csaba</span> <span class="authorAux-mtmt"> Sugárterápia, klinikai onkológia</span>) </a> </span> <span class="author-affil">National Institute of Oncology; <span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Onkológiai Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10023482"><a href="/gui2/?type=authors&mode=browse&sel=10023482" target="_blank">Kapitány Z (<span class="authorship-author-name">Kapitány Zsuzsanna</span> <span class="authorAux-mtmt"> Emésztőrendszeri daganatos betegek fizioterápiá...</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Health Sciences">FHS</span>/Department of Physiotherapy</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10067729"><a href="/gui2/?type=authors&mode=browse&sel=10067729" target="_blank">Koncz Z (<span class="authorship-author-name">Koncz Zsuzsa</span> <span class="authorAux-mtmt"> klinikai szakpszichológus</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Department of Behavioral Sciences</span> </div> <div class="autype autype-29"> Collaborative Organization: <span class="author-affil">Central-Eastern European Academy of Oncology (CEEAO) International Professional Panel</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;32946435" target="_blank">Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer</a></div> <div> <span class="journal-title">PATHOLOGY AND ONCOLOGY RESEARCH</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1219-4956">1219-4956</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1532-2807">1532-2807</a>)</span>: <span class="journal-volume">28</span> <span class="page"> Paper 1610383. 26 p. </span> <span class="year">(2022)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Language: English | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.3389/pore.2022.1610383" target="_blank" href="https://doi.org/10.3389/pore.2022.1610383"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000831832300001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000831832300001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85133540628" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85133540628"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="35898593" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35898593&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_GREEN" title=" Green "> <a style="color:blue" title="37582" target="_blank" href="http://publicatio.bibl.u-szeged.hu/37582"> SZTE Publicatio </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Journal subject: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q2</div> <div class="journal-subject">Journal subject: Scopus - Pathology and Forensic Medicine&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q2</div> <div class="journal-subject">Journal subject: Scopus - Cancer Research&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q3</div> <div class="journal-subject">Journal subject: Scopus - Oncology&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q3</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="" class="citingPub-count">Citing papers: 24</span> | Independent citation: 17 | Self citation: 7 | Unknown citation: 0 | Number of citations in WoS: 23 | Number of citations in Scopus:&nbsp;20 | WoS/Scopus assigned:&nbsp;24 | Number of citations with DOI:&nbsp;23 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;32946435&sort=publishedYear,desc&sort=title"> Number of cited publications: 10 </a> </div> <div class="mtid"><span class="long-pub-mtid">Publication: 32946435</span> | <span class="status-data status-VALIDATED"> Validated </span> Core Citing | <span class="type-subtype">Journal Article ( Study Group ) </span> | <span class="pub-category">Scientific</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="lastModified">Last Modified: 2025.11.03. 13:46 Anita Nicsinger (PTE ETK admin 5) </div> <div class="lockedBy">Centrally managed 2024.10.17. 18:16 Gusztáv Ladányi (MTMT API user, admin) Katalin Kériné Tornyi (MTMT ellenőrzés admin5) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Comments</u>: Funding Agency and Grant Number: Central Eastern European Academy of Oncology Foundation; National Institute of Oncology Funding text: The publication fee is covered by funding of the Central Eastern European Academy of Oncology Foundation, National Institute of Oncology 1122 Budapest Rath Gy. u 7-9.</pre> </div></div>